MARKET

TGTX

TGTX

Tg Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.570
+0.320
+7.53%
After Hours: 4.450 -0.12 -2.63% 17:49 07/01 EDT
OPEN
4.230
PREV CLOSE
4.250
HIGH
4.580
LOW
4.220
VOLUME
2.34M
TURNOVER
0
52 WEEK HIGH
41.00
52 WEEK LOW
3.480
MARKET CAP
660.07M
P/E (TTM)
-1.8585
1D
5D
1M
3M
1Y
5Y
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with
Benzinga · 5d ago
BRIEF-TG Therapeutics Announces Presentation Of Exploratory Analyses From The Ultimate I & Ii Phase 3 Trials Of Ublituximab In Multiple Sclerosis At The 8Th Congress Of The European Academy Of Neurology
BRIEF-TG Therapeutics Announces Presentation Of Exploratory Analyses From The Ultimate I & Ii Phase 3 Trials Of Ublituximab In Multiple Sclerosis At The 8Th Congress Of The European Academy Of Neurology
Reuters · 5d ago
Valneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar?
Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks · 06/22 11:43
5 Analysts Have This to Say About TG Therapeutics
Analysts have provided the following ratings for TG Therapeutics (NASDAQ:TGTX) within the last quarter:
Benzinga · 06/13 13:12
B. Riley Lowers TG Therapeutics' Price Target to $17 from $23, Notes Market Size/Growth Dynamics; Reiterates Buy Rating
MT Newswires · 06/13 09:01
TG Therapeutics (NASDAQ:TGTX) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Simply Wall St. · 06/12 14:17
TG Therapeutics (TGTX) Soars 18.7%: Is Further Upside Left in the Stock?
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks · 06/09 13:20
TGTX, MULN and EFOI among pre market gainers
Turning Point Therapeutics (TPTX) +116% Bristol Myers to acquire Turning Point Therapeutics for over $4B in cash. The Marygold Companies (MGLD) +32%. Energy Focus (EFOI) +26%. Amylyx Pharmaceuticals (AMLX) +23% as FDA extends review
Seekingalpha · 06/03 12:49
More
No Data
Learn about the latest financial forecast of TGTX. Analyze the recent business situations of Tg Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

22.22%Strong Buy
55.56%Buy
0.00%Hold
22.22%Under-perform
0.00%Sell
Analyst Price Target
The average TGTX stock price target is 16.88 with a high estimate of 40.00 and a low estimate of 4.000.
High40.00
Average16.88
Low4.000
Current 4.570
EPS
Actual
Estimate
-0.56-0.42-0.28-0.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 250
Institutional Holdings: 120.60M
% Owned: 83.50%
Shares Outstanding: 144.44M
TypeInstitutionsShares
Increased
72
13.33M
New
31
3.55M
Decreased
45
5.00M
Sold Out
43
11.08M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Weiss
Chief Financial Officer/Treasurer/Secretary
Sean Power
Lead Director/Independent Director
Laurence Charney
Independent Director
Yann Echelard
Independent Director
Kenneth Hoberman
Independent Director
Daniel Hume
Independent Director
Sagar Lonial
No Data
No Data
About TGTX
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).

Webull offers kinds of TG Therapeutics Inc stock information, including NASDAQ:TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.